Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT06339411
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT06339411
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06339411. Randomized; triple masking; primary purpose treatment. Start 2026-09-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy
- Acronym
- CARE-EVT
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Cerebrolysin
- Intervention (Drug)
- Normal saline placebo
- Lead sponsor
- Chang Gung Memorial Hospital
- Collaborator
- EVER Pharma France SAS
Record details
- Record id
cardio:ct-nct06339411- Content hash
f5109981fe80e8707430b24f05a63fa760113a4a0ee5991d84250370e00fd7df